Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Pizzuti L, et al. Among authors: marchetti p, marchetti l. Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16. Cancer Biol Ther. 2018. PMID: 29336662 Free PMC article.
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, DI Rocco ZC, Natoli C, Tinari N, DE Galitiis F, Calista F, Marchetti P. Ficorella C, et al. Among authors: marchetti p. Br J Cancer. 2004 Aug 16;91(4):618-20. doi: 10.1038/sj.bjc.6601971. Br J Cancer. 2004. PMID: 15292944 Free PMC article. Clinical Trial.
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Buffone A, et al. Among authors: marchetti p. Breast Cancer Res Treat. 2007 Dec;106(2):289-96. doi: 10.1007/s10549-007-9499-6. Epub 2007 Feb 28. Breast Cancer Res Treat. 2007. PMID: 17333342
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: marchetti p. BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567. BMC Cancer. 2010. PMID: 20958992 Free PMC article. Clinical Trial.
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: marchetti p. Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27. Clin Colorectal Cancer. 2012. PMID: 22206922 Clinical Trial.
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E. Lazzaro C, et al. Among authors: marchetti p. Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013. Clinicoecon Outcomes Res. 2013. PMID: 23610525 Free PMC article.
1,472 results